Loading...
Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractor...
Saved in:
| Published in: | Exp Hematol Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
BioMed Central
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7784272/ https://ncbi.nlm.nih.gov/pubmed/33397455 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-020-00186-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|